Skip to main content

Advertisement

Table 1 Baseline demographic and clinical characteristics of adolescents with schizophrenia

From: An open-label, multicenter evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophrenia

Parameter PBO/RIS RIS/RIS Direct-enroll All subjects
(n = 48) (n = 292) (n = 50) (N = 390)
Age, mean (SD), y 15.4 (1.4) 15.5 (1.7) 15.5 (1.4) 15.5 (1.6)
Sex, n (%)     
Female 18 (38) 114 (39) 20 (40) 152 (39)
Male 30 (63) 178 (61) 30 (60) 238 (61)
Weight, mean (SD), kg 59.2 (20.9) 60.3 (13.4) 67.3 (14.2) 61.0 (14.8)
Body mass index, mean (SD), kg/m2 21.8 (5.9) 21.5 (3.6) 22.5 (4.0) 21.7 (4.0)
Maximum Tanner stage, n (%)     
1 0 6 (2) 0 6 (2)
2 3 (6) 2 (1) 1 (2) 6 (2)
3 11 (23) 32 (11) 2 (4) 45 (12)
4 21 (45) 112 (42) 26 (52) 169 (44)
5 12 (26) 128 (44) 21 (42) 161 (42)
Race, n (%)     
White 25 (52) 218 (75) 42 (84) 285 (73)
Black or African American 4 (8) 39 (13) 8 (16) 51 (13)
Asian 19 (40) 31 (11) 0 50 (13)
Mixed 0 2 (1) 0 2 (1)
American Indian/Native Alaskan 0 1 (<1) 0 1 (<1)
Axis diagnosis, n (%)     
Schizophrenia 48 (100) 288 (99) 50 (100) 386 (99)
Schizophreniform disorder 0 4 (1) 0 4 (1)
Diagnosis, n (%)     
Paranoid 33 (69) 195 (67) 35 (70) 263 (67)
Undifferentiated 11 (23) 55 (19) 13 (26) 79 (20)
Disorganized 3 (6) 26 (9) 2 (4) 31 (8)
Residual 1 (2) 6 (2) 0 7 (2)
Catatonic 0 6 (2) 0 6 (2)
Schizophreniform disorder 0 4 (1) 0 4 (1)
Age at diagnosis, mean (SD), y 14.8 (1.6) 14.9 (2.2) 15.1 (1.9) 14.9 (2.1)
Age at first psychotic symptoms, mean (SD), y 12.6 (3.1) 13.4 (2.9) 13.6 (2.5) 13.3 (2.9)
Age at start of antipsychotic treatment, mean (SD), y 13.9 (2.6) 14.6 (2.3) 14.8 (1.9) 14.5 (2.3)
Time since onset of first psychotic symptoms, mean (SD), y 2.8 (2.4) 2.1 (2.3) 1.9 (2.0) 2.1 (2.3)